{"schema_version":"secwatch.filing_event.v1","accession":"0001724521-24-000090","form_type":"8-K","ticker":"RCUS","cik":"0001724521","company_name":"Arcus Biosciences, Inc.","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.749714+00:00","generated_at":"2026-06-02T11:47:36.378240+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Arcus Q1 revenue jumps to $145M, net loss $4M; pipeline advances with ASCO presentations and Phase 3 enrollments","bullets":["Revenue $145M vs $25M YoY, including $135M license revenue from Gilead collaboration amendments.","Net loss $4M vs $80M YoY; cash $1.1B at quarter end; year-end 2024 cash expected $870-920M.","R&D expenses $109M (up from $81M); $20M impairment charge for facility sublease.","Two oral presentations at ASCO 2024: EDGE-Gastric (domvanalimab) and ARC-9 (etrumadenant) in GI cancers.","Phase 3 STAR-221 enrollment expected mid-2024; STAR-121 H2 2024; first Phase 3 for casdatifan in ccRCC planned H1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001724521-24-000090","json":"https://secwatch.observer/filing/0001724521-24-000090.json","markdown":"https://secwatch.observer/filing/0001724521-24-000090.md","text":"https://secwatch.observer/filing/0001724521-24-000090.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1724521/000172452124000090/0001724521-24-000090-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1724521/000172452124000090/rcus-20240508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T11:47:36.378240+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2fc46321985a390e7a64c73826a98e94e1a07c38","claim":"Arcus Biosciences, Inc. reported the first quarter ended March 31, 2024 results: revenue $145 million.","evidence_excerpt":"to fund operations into 2027. Cash, cash equivalents and marketable securities are expected to be between $870 million and $920 million at the end of 2024. • Revenues were $145 million for the first quarter 2024, compared to $25 million for the same period in 2023. In the first quarter 2024, Arcus recognized $135 million in license and development services","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1724521/000172452124000090/0001724521-24-000090-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Revenue","value":"$145 million"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}